Skip to main content
Premium Trial:

Request an Annual Quote

Index Ventures Closes $300M Fund for IT, Life Science Companies

NEW YORK, July 9 – Index Ventures has closed a new $300 million fund to target information technology and life sciences companies in Europe, the firm said Monday.

A spokeswoman said the firm would target life science businesses developing post-genomic platforms, therapeutics, and nanotechnology.

Index, based in Geneva, Switzerland, would most likely devote about 30 percent of the fund to life science companies, the spokeswoman said. Index has invested in six or seven biotechnology companies in the past, including Genmab, a developer of fully-human antibodies based in Copenhagen, Denmark, and Cellzome, a functional proteomics company based in Heidelberg, Germany. 

With the current fund, Index Ventures II, the firm will focus slightly more heavily on life sciences than in the past, according to the company. Index now has a four-person team devoted to identifying early-stage life science companies.

Index invests primarily in European companies, but does consider US and Israeli companies that have early intentions to expand into Europe, or have strategic partnerships with European companies.

Investors in the current fund include UBS Capital, LGT Capital Partners, HarbourVest, and Standard Life Investments.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.